vs

Side-by-side financial comparison of IMMERSION CORP (IMMR) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

IMMERSION CORP is the larger business by last-quarter revenue ($372.9M vs $207.3M, roughly 1.8× Ultragenyx Pharmaceutical Inc.). IMMERSION CORP runs the higher net margin — -4.6% vs -62.0%, a 57.5% gap on every dollar of revenue. On growth, IMMERSION CORP posted the faster year-over-year revenue change (750.4% vs 25.9%). Over the past eight quarters, IMMERSION CORP's revenue compounded faster (537.9% CAGR vs 38.0%).

Immersion Corporation is an Aventura, Florida based developer and licensor of touch feedback technology, also known as haptic technology. Immersion Corporation has been accused of being a patent troll. Founded in 1993 by Louis Rosenberg, it is currently headed by lawyer Francis Jose, who serves as both chief executive officer and general counsel.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

IMMR vs RARE — Head-to-Head

Bigger by revenue
IMMR
IMMR
1.8× larger
IMMR
$372.9M
$207.3M
RARE
Growing faster (revenue YoY)
IMMR
IMMR
+724.5% gap
IMMR
750.4%
25.9%
RARE
Higher net margin
IMMR
IMMR
57.5% more per $
IMMR
-4.6%
-62.0%
RARE
Faster 2-yr revenue CAGR
IMMR
IMMR
Annualised
IMMR
537.9%
38.0%
RARE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMMR
IMMR
RARE
RARE
Revenue
$372.9M
$207.3M
Net Profit
$-17.0M
$-128.6M
Gross Margin
Operating Margin
-2.8%
-54.7%
Net Margin
-4.6%
-62.0%
Revenue YoY
750.4%
25.9%
Net Profit YoY
-191.3%
3.5%
EPS (diluted)
$-0.57
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMMR
IMMR
RARE
RARE
Q4 25
$207.3M
Q3 25
$159.9M
Q2 25
$372.9M
$166.5M
Q1 25
$471.3M
$139.3M
Q4 24
$616.2M
$164.6M
Q3 24
$139.5M
Q2 24
$95.5M
$147.0M
Q1 24
$43.8M
$108.8M
Net Profit
IMMR
IMMR
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-180.4M
Q2 25
$-17.0M
$-115.0M
Q1 25
$24.1M
$-151.1M
Q4 24
$30.8M
$-133.2M
Q3 24
$-133.5M
Q2 24
$26.4M
$-131.6M
Q1 24
$18.7M
$-170.7M
Operating Margin
IMMR
IMMR
RARE
RARE
Q4 25
-54.7%
Q3 25
-106.9%
Q2 25
-2.8%
-64.8%
Q1 25
7.5%
-102.6%
Q4 24
11.4%
-74.3%
Q3 24
-94.6%
Q2 24
23.7%
-79.1%
Q1 24
37.9%
-151.9%
Net Margin
IMMR
IMMR
RARE
RARE
Q4 25
-62.0%
Q3 25
-112.8%
Q2 25
-4.6%
-69.0%
Q1 25
5.1%
-108.5%
Q4 24
5.0%
-80.9%
Q3 24
-95.7%
Q2 24
27.7%
-89.5%
Q1 24
42.5%
-156.8%
EPS (diluted)
IMMR
IMMR
RARE
RARE
Q4 25
$-1.28
Q3 25
$-1.81
Q2 25
$-0.57
$-1.17
Q1 25
$0.73
$-1.57
Q4 24
$0.93
$-1.34
Q3 24
$-1.40
Q2 24
$0.81
$-1.52
Q1 24
$0.59
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMMR
IMMR
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$161.4M
$421.0M
Total DebtLower is stronger
$103.1M
Stockholders' EquityBook value
$298.1M
$-80.0M
Total Assets
$1.1B
$1.5B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMMR
IMMR
RARE
RARE
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$161.4M
$176.3M
Q1 25
$153.9M
$127.1M
Q4 24
$159.3M
$174.0M
Q3 24
$150.6M
Q2 24
$133.4M
$480.7M
Q1 24
$179.1M
$112.3M
Total Debt
IMMR
IMMR
RARE
RARE
Q4 25
Q3 25
Q2 25
$103.1M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IMMR
IMMR
RARE
RARE
Q4 25
$-80.0M
Q3 25
$9.2M
Q2 25
$298.1M
$151.3M
Q1 25
$317.9M
$144.2M
Q4 24
$305.5M
$255.0M
Q3 24
$346.8M
Q2 24
$273.4M
$432.4M
Q1 24
$201.5M
$140.3M
Total Assets
IMMR
IMMR
RARE
RARE
Q4 25
$1.5B
Q3 25
$1.2B
Q2 25
$1.1B
$1.3B
Q1 25
$1.4B
$1.3B
Q4 24
$1.4B
$1.5B
Q3 24
$1.5B
Q2 24
$1.2B
$1.6B
Q1 24
$244.7M
$1.3B
Debt / Equity
IMMR
IMMR
RARE
RARE
Q4 25
Q3 25
Q2 25
0.35×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMMR
IMMR
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMMR
IMMR
RARE
RARE
Q4 25
$-99.8M
Q3 25
$-91.4M
Q2 25
$-108.3M
Q1 25
$-43.7M
$-166.5M
Q4 24
$-79.3M
Q3 24
$-67.0M
Q2 24
$-85.9M
$-77.0M
Q1 24
$29.9M
$-190.7M
Free Cash Flow
IMMR
IMMR
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-46.2M
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
IMMR
IMMR
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-9.8%
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
IMMR
IMMR
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
0.5%
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
IMMR
IMMR
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
-1.82×
Q4 24
Q3 24
Q2 24
-3.25×
Q1 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMMR
IMMR

Course Material Sale$150.9M40%
General Merchandise Sale$138.0M37%
Rental Services$51.8M14%
Services And Other Revenue$25.6M7%
Per Unit Royalties$1.8M0%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons